Pharma Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Business & Finance
Allergan extends expiration date of exchange offer
February 27th, 2006
Allergan, Inc., (AGN) announced that it is extending the expiration date of its exchange offer for all outstanding shares of common stock of Inamed Corp. (IMDC). The exchange offer is being extended as U.S. antitrust approval of the Inamed acquisition has not yet been received, and was set to expire on February 22, 2006. Approximately 19,329,021 shares, or approximately 52.4%, of Inamed's outstanding common stock had been tendered as of 5:00 p.m. Eastern Time on Friday, February 3, 2006. Allergan and Inamed are continuing to work with the Federal Trade Commission to complete Inamed's divestiture of its Reloxin license to facilitate U.S. antitrust...
Source: Pharma Business Week (2006-02-27)
|
